Quarterly Result31 Jul 2025, 02:37 pm
Sun Pharmaceutical Reports Q1 FY 2025-26 Financial Results with 14.72% Increase in Profit Before Exceptional Items and Tax
AI Summary
Sun Pharmaceutical Industries Ltd. has reported its financial results for the quarter ended 30 June 2025, showing an increase in profit before exceptional items and tax by 14.72% compared to the same period last year. The company's revenue from operations stands at INR 56,019.6 million, INR 71,857.4 million, and INR 44,980.7 million for the quarter, nine months, and year ended 30 June 2025, respectively. The profit before tax for the quarter, nine months, and year ended 30 June 2025 is INR 11,848.8 million, INR 26,120.8 million, and INR 2,579.2 million, respectively. The company has also announced changes in the composition of the Board Committees.
Key Highlights
- Sun Pharmaceutical reports a 14.72% increase in profit before exceptional items and tax for Q1 FY 2025-26
- Revenue from operations for Q1, nine months, and year ended 30 June 2025 stands at INR 56,019.6 million, INR 71,857.4 million, and INR 44,980.7 million, respectively
- Profit before tax for Q1, nine months, and year ended 30 June 2025 is INR 11,848.8 million, INR 26,120.8 million, and INR 2,579.2 million, respectively
- Changes in the composition of the Board Committees announced
- The company has one reportable segment: 'Pharmaceuticals'